Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InflaRx ( (IFRX) ) just unveiled an announcement.
On May 6, 2026, InflaRx N.V. signed an underwriting agreement with Guggenheim Securities for an underwritten public offering of 75 million ordinary shares at $2.00 per share, which closed on May 7, 2026. The transaction, conducted under the company’s existing F-3 shelf registration, generated gross proceeds of about $150 million before underwriting discounts and expenses, reinforcing InflaRx’s capital position and expanding its U.S.-listed share base through a large, SEC-registered equity issuance.
The company granted customary representations, warranties and indemnification to the underwriting syndicate, aligning the deal with standard U.S. capital markets practice. Legal opinions from NautaDutilh N.V. supported the validity of the share issuance, and the Form 6-K filing ensures the offering documents are incorporated by reference into InflaRx’s existing SEC registration statements, streamlining future securities-related filings and disclosures.
The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, sizable ongoing losses, and persistent cash burn) and limited valuation support (negative P/E, no dividend). These are partially offset by strong recent technical momentum with the stock trading well above key moving averages, though overbought signals increase near-term risk.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V., based in Jena, Germany, is a Dutch-incorporated biopharmaceutical company whose ordinary shares trade in the U.S. It focuses on developing and commercializing therapies, typically funded through public equity offerings registered with the U.S. Securities and Exchange Commission, to advance its pipeline and corporate operations in global markets.
Average Trading Volume: 1,037,804
Technical Sentiment Signal: Buy
Current Market Cap: $180.7M
Learn more about IFRX stock on TipRanks’ Stock Analysis page.